Rhinomed Mute Granted US FDA Registration
Sydney, Dec 3, 2014 - (ABN Newswire) - Melbourne technology firm, Rhinomed (ASX:RNO) is pleased to announce that it has successfully completed the testing and technical documentation that has enabled its new novel snoring and sleep quality product - Mute(TM) to gain acceptance with the US Food and Drug Administration(FDA), European authority (CE Mark) and the Australian Therapeutic Goods Association (TGA).
The Mute(TM) is an internal nasal dilator that increases airflow, which allows people to breathe more and snore less. In a recently independently conducted trial results announced 2nd December 2014, the Mute(TM) achieved the primary endpoints - significant reduction in snoring severity, volume, frequency and duration.
The trial (n=236) exceeded in pre-specified criteria showing clear improvement in reported sl eep quality in both snorer and partner.
Successfully registering the Mute(TM) with the US FDA as a Class 1, 510(k) exempt medical device product allows the Mute(TM) to be sold online and in store within the United States of America.
A market where, according to the US National Institutes of Health (NIH), close to 70% of the adult population suffers from poor sleep quality. Conforming to the regulatory and manufacturing requirements necessary to receive a CE Mark opens the way for the Mute(TM) to be marketed directly to European consumers, as well to consumers in the four member states of the European Free Trade Association and in Turkey.
Australian TGA registration ensures that the company can commence its test-marketing program immediately. This is a critical step in the planned roll out of the Mute(TM) technology.
Rhinomed CEO Michael Johnson said, "The testing, process and steps we put in place for the our first product - the Turbine(TM) - ensured that our second technology - Mute(TM) was right from the start designed, tested and manufactured to fully comply with the most rigorous of regulatory requirements.
Our internal team and regulatory advisors have done a great job of ensuring that we built the required testing and quality control processes that have enabled the Mute(TM) to comply with ISO Standard 13485 for the development of medical devices and to be successfully registered with the European, US and Australian Authorities."
WEB: Mute Granted US FDA Registration
About: Rhinomed Limited
Rhinomed Limited is a medical technology firm that focuses on nasal, respiratory and breathing management technologies. The company is monetising its technology portfolio in the Sport and recreation market, Sleep, Wellbeing and Drug delivery markets.
Rhinomed's technology is designed to radically improve the way you breathe sleep, maintain your health and take medication.
The first product brought to market is the Turbine(TM). A radical nasal technology that improves airflow by an average of 38%, the Turbine(TM) is an internal nasal dilator that has since it's launch in January 2014 in Australia, grown to be widely adopted by leading cyclists and triathletes globally.
Now shipped to over 36 countries and with a growing global distribution base, the Turbine(TM) is providing all those undertaking aerobic activities with an opportunity to breathe better, perform better and get more enjoyment from their sport and exercise.
Contact:
Media Enquiries
Michael Johnson
CEO & Managing Director
T: +61 (03) 8416 0900
mjohnson@rhinomed.com.au
Follow us on twitter @rhinomedceo
Help employers find you! Check out all the jobs and post your resume.
The Mute(TM) is an internal nasal dilator that increases airflow, which allows people to breathe more and snore less. In a recently independently conducted trial results announced 2nd December 2014, the Mute(TM) achieved the primary endpoints - significant reduction in snoring severity, volume, frequency and duration.
The trial (n=236) exceeded in pre-specified criteria showing clear improvement in reported sl eep quality in both snorer and partner.
Successfully registering the Mute(TM) with the US FDA as a Class 1, 510(k) exempt medical device product allows the Mute(TM) to be sold online and in store within the United States of America.
A market where, according to the US National Institutes of Health (NIH), close to 70% of the adult population suffers from poor sleep quality. Conforming to the regulatory and manufacturing requirements necessary to receive a CE Mark opens the way for the Mute(TM) to be marketed directly to European consumers, as well to consumers in the four member states of the European Free Trade Association and in Turkey.
Australian TGA registration ensures that the company can commence its test-marketing program immediately. This is a critical step in the planned roll out of the Mute(TM) technology.
Rhinomed CEO Michael Johnson said, "The testing, process and steps we put in place for the our first product - the Turbine(TM) - ensured that our second technology - Mute(TM) was right from the start designed, tested and manufactured to fully comply with the most rigorous of regulatory requirements.
Our internal team and regulatory advisors have done a great job of ensuring that we built the required testing and quality control processes that have enabled the Mute(TM) to comply with ISO Standard 13485 for the development of medical devices and to be successfully registered with the European, US and Australian Authorities."
WEB: Mute Granted US FDA Registration
About: Rhinomed Limited
Rhinomed Limited is a medical technology firm that focuses on nasal, respiratory and breathing management technologies. The company is monetising its technology portfolio in the Sport and recreation market, Sleep, Wellbeing and Drug delivery markets.
Rhinomed's technology is designed to radically improve the way you breathe sleep, maintain your health and take medication.
The first product brought to market is the Turbine(TM). A radical nasal technology that improves airflow by an average of 38%, the Turbine(TM) is an internal nasal dilator that has since it's launch in January 2014 in Australia, grown to be widely adopted by leading cyclists and triathletes globally.
Now shipped to over 36 countries and with a growing global distribution base, the Turbine(TM) is providing all those undertaking aerobic activities with an opportunity to breathe better, perform better and get more enjoyment from their sport and exercise.
Contact:
Media Enquiries
Michael Johnson
CEO & Managing Director
T: +61 (03) 8416 0900
mjohnson@rhinomed.com.au
Follow us on twitter @rhinomedceo
Help employers find you! Check out all the jobs and post your resume.